title: Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer.
abstract: The purpose of this study was to compare chemotherapy-naive patients with stage IV nonsmall cell lung cancer patients treated with chemotherapy or chemoimmunotherapy. We tested doxetacel plus cisplatinum as chemotherapy protocol. An immunomodulatory adjuvant system was added as chemoimmunotherapy to the previously mentioned protocol. This system contains three well-known and complementary conditioners of protective immune-responses: cyclophosphamide low-dose, granulocyte macrophage-colony stimulant factor and magnesium silicate granuloma. Eighty-eight patients were randomly assigned to receive every 3-weeks one of the treatments under comparison. Patients received four cycles of treatment unless disease progression or unacceptable toxicity was documented. The maximum follow-up was one year. In each arm, tumor response (rate,duration), median survival time, 1-year overall survival, safety, and immunity modifications were assessed. Immunity was evaluated by submitting peripheral blood mononuclear cells to laboratory tests for nonspecific immunity: a) phytohemaglutinin-induced lymphocyte proliferation, b) prevalence of T-Regulatory (CD4+CD25+) cells and for specific immunity: a) lymphocyte proliferation induced by tumor-associated antigens (TAA) contained in a previously described autologous thermostable hemoderivative. The difference (chemotherapy vs. chemoimmunotherapy) in response rate induced by the two treatments (39.0% and 35.0%) was not statistically significant. However, the response duration (22 and 31 weeks), the median survival time (32 and 44 weeks) and 1-year survival (33.3% and 39.1%) were statistically higher with chemoimmunotherapy. No difference in toxicity between both arms was demonstrated. A switch in the laboratory immunity profile, nonspecific and specific, was associated with the chemoimmunotherapy treatment: increase of proliferative lymphocyte response, decrease of tolerogenic T-regulatory cells and eliciting TAA-sensitization.
authors.affiliation: Interdoctors Medical Procedures, North Miami Beach, FL, USA;
authors.forename: Eduardo
authors.initials: E
authors.lastname: Lasalvia-Prisco
authors.forename: Emilio
authors.initials: E
authors.lastname: Garcia-Giralt
authors.forename: Jesús
authors.initials: J
authors.lastname: Vázquez
authors.forename: Marta
authors.initials: M
authors.lastname: Aghazarian
authors.forename: Eduardo
authors.initials: E
authors.lastname: Lasalvia-Galante
authors.forename: Joshemaria
authors.initials: J
authors.lastname: Larrañaga
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Spera
references.citation: Chest. 2003 Jan;123(1 Suppl):226S-243S
references.pmid: 12527582
references.citation: Am J Clin Oncol. 1982 Dec;5(6):649-55
references.pmid: 7165009
references.citation: Med Oncol. 2006;23(1):91-104
references.pmid: 16645234
references.citation: Clin Med Res. 2005 Nov;3(4):221-8
references.pmid: 16303887
references.citation: Immunol Rev. 2002 Oct;188:147-54
references.pmid: 12445288
references.citation: Ann Immunol (Paris). 1977 Jul-Oct;128C(4-5):923-8
references.pmid: 900902
references.citation: Oncologist. 2000;5(6):497-500
references.pmid: 11110601
references.citation: Blood. 2002 Dec 1;100(12):4108-15
references.pmid: 12393401
references.citation: J Urol. 2006 Jun;175(6):2087-91
references.pmid: 16697809
references.citation: Ann Intern Med. 2001 Apr 17;134(8):663-94
references.pmid: 11304107
references.citation: Proc Natl Acad Sci U S A. 1983 Oct;80(20):6395-8
references.pmid: 6578514
references.citation: Eur J Immunol. 2004 Feb;34(2):336-44
references.pmid: 14768038
references.citation: Ann N Y Acad Sci. 1979;332:135-47
references.pmid: 316979
references.citation: Cancer Biol Ther. 2003 Mar-Apr;2(2):155-60
references.pmid: 12750554
references.citation: Blood. 1996 Jul 1;88(1):202-10
references.pmid: 8704175
references.citation: Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S115-24
references.pmid: 17259552
references.citation: J Mol Med (Berl). 1999 Dec;77(12):824-33
references.pmid: 10682318
references.citation: Lancet. 2001 Apr 14;357(9263):1191-4
references.pmid: 11323066
references.citation: Immunol Lett. 1987 Dec;16(3-4):199-203
references.pmid: 3443469
references.citation: Proc Natl Acad Sci U S A. 1992 May 15;89(10):4358-62
references.pmid: 1584770
references.citation: J Clin Oncol. 2004 Jul 1;22(13):2602-9
references.pmid: 15226327
references.citation: Nat Med. 1998 May;4(5):581-7
references.pmid: 9585232
references.citation: Clin Trials. 2006;3(4):335-48
references.pmid: 17060208
references.citation: Neoplasma. 1982;29(1):93-110
references.pmid: 6280082
references.citation: Breast Cancer Res Treat. 2006 Nov;100(2):149-60
references.pmid: 16819567
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Biologics. 2007 Jun;1(2):173-81
references.pmid: 19707327
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: Cancer Treat Rep. 1978 Jul;62(7):1059-63
references.pmid: 356968
references.citation: Cancer Res. 1982 Nov;42(11):4862-6
references.pmid: 7127320
references.citation: Nat Rev Immunol. 2006 Sep;6(9):659-70
references.pmid: 16932751